drugset / Trial / NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Phase 2/3
Recruiting
176 enrolled
Vertex Pharmaceuticals Incorporated
Zai Lab (Shanghai) Co., Ltd. (for China only) · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Timeline
- Start
- 2025-09-30
- Primary completion
- 2028-12-29
- Completion
- 2028-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Povetacicept | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Tacrolimus | Small molecule | — | Oral |